A
Arlene B. Chapman
Researcher at University of Chicago
Publications - 298
Citations - 16910
Arlene B. Chapman is an academic researcher from University of Chicago. The author has contributed to research in topics: Autosomal dominant polycystic kidney disease & Polycystic kidney disease. The author has an hindex of 66, co-authored 281 publications receiving 14251 citations. Previous affiliations of Arlene B. Chapman include University of Colorado Boulder & Emory University.
Papers
More filters
Journal ArticleDOI
Tolvaptan in patients with autosomal dominant polycystic kidney disease
Vicente E. Torres,Arlene B. Chapman,Olivier Devuyst,Olivier Devuyst,Ron T. Gansevoort,Jared J. Grantham,Eiji Higashihara,Ronald D. Perrone,Holly B. Krasa,John Ouyang,Frank S. Czerwiec +10 more
TL;DR: Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events.
Journal ArticleDOI
Volume Progression in Polycystic Kidney Disease
Jared J. Grantham,Vicente E. Torres,Arlene B. Chapman,Lisa M. Guay-Woodford,Kyongtae T. Bae,Bernard F. King,Louis H. Wetzel,Deborah A. Baumgarten,Phillip J. Kenney,Peter C. Harris,Saulo Klahr,William M. Bennett,Gladys N. Hirschman,Catherine M. Meyers,Xiaoling Zhang,Fang Zhu,J. P. Miller +16 more
TL;DR: Kidney enlargement resulting from the expansion of cysts in patients with ADPKD is continuous and quantifiable and is associated with the decline of renal function.
Journal ArticleDOI
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Arlene B. Chapman,Olivier Devuyst,Kai-Uwe Eckardt,Ron T. Gansevoort,Tess Harris,Shigeo Horie,Bertram L. Kasiske,Dwight Odland,York Pei,Ronald D. Perrone,Yves Pirson,Robert W. Schrier,Roser Torra,Vicente E. Torres,Terry Watnick,David C. Wheeler +15 more
TL;DR: This review summarized areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support that are summarized in this review.
Journal ArticleDOI
Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials
Maria V. Irazabal,Laureano J. Rangel,Eric J. Bergstralh,Sara L. Osborn,Amber J. Harmon,Jamie L. Sundsbak,Kyongtae T. Bae,Arlene B. Chapman,Jared J. Grantham,Michal Mrug,Marie C. Hogan,Ziad M. El-Zoghby,Peter C. Harris,Bradley J. Erickson,Bernard F. King,Vicente E. Torres +15 more
TL;DR: A longitudinal mixed regression model to predict eGFR decline showed that log2HtTKV and age significantly interacted with time in typical patients, but not in atypical patients.
Journal ArticleDOI
Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Robert W. Schrier,Robert W. Schrier,Kaleab Z. Abebe,Ronald D. Perrone,Vicente E. Torres,William E. Braun,Theodore I. Steinman,Franz T. Winklhofer,Godela Brosnahan,Peter G. Czarnecki,Marie C. Hogan,Dana C. Miskulin,Frederic F. Rahbari-Oskoui,Jared J. Grantham,Peter C. Harris,Michael F. Flessner,Kyongtae T. Bae,Charity G. Moore,Arlene B. Chapman +18 more
TL;DR: In early ADPKD, the combination of lisinopril and telmisartan did not significantly alter the rate of increase in total kidney volume and rigorous blood-pressure control was associated with a slower increase inTotal kidney volume, no overall change in the estimated GFR, a greater decline in the left-ventricular-mass index, and greater reduction in urinary albumin excretion.